文献速递肾癌与肾肿瘤

应用机器学习模型预测非转移性肾细胞癌手术切除后复发

Application of Machine Learning Models to Predict Recurrence After Surgical Resection of Nonmetastatic Renal Cell Carcinoma.
PubMed 文献 · Eur Urol Oncol · 2022-08-18

本研究在2013至2020年间法国21个医疗中心接受根治性或部分肾切除术的非转移性肾细胞癌患者中构建并验证多种机器学习模型(随机生存森林、生存支持向量机、极端梯度提升),并与四种传统预后模型比较。共纳入4067例患者,中位随访57个月,523例(13%)复发。机器学习模型的一致指数高于传统模型,随机生存森林最高(0.794),且决策曲线分析显示机器学习模型带来增量净获益。

要点

  • 机器学习模型预测非转移性肾细胞癌术后复发的一致指数高于传统模型。
  • 随机生存森林模型一致指数最高(0.794),其次为生存支持向量机(0.784)和极端梯度提升(0.782)。
  • 所有模型校准良好(整合Brier评分均<0.1),但随时间出现校准漂移,机器学习模型幅度较小。

核心结论

  • 应用机器学习方法预测肾细胞癌手术切除后复发,其预测性能优于当前临床实践中已验证的模型。
  • 仍有改进空间,可能来自新型生物学和/或影像生物标志物的整合。

研究设计与样本

  • 观察性研究,在2013至2020年间法国21个医疗中心接受根治性或部分肾切除术的非转移性肾细胞癌患者中构建并测试机器学习模型(随机生存森林、生存支持向量机、极端梯度提升)。
  • 共纳入4067例患者(开发队列3253例,验证队列814例)。

主要发现

  • 大多数肿瘤(69%)为透明细胞肾细胞癌,40%为高级别(国际泌尿病理学会核分级3或4级),24%有坏死,4%有淋巴结受累。
  • 中位随访57个月(四分位距29-76),523例(13%)患者复发。
  • 机器学习模型的一致指数高于传统模型:随机生存森林最高(0.794),生存支持向量机为0.784,极端梯度提升为0.782。
  • 所有模型校准良好(整合Brier评分均<0.1),但所有模型随时间出现校准漂移,机器学习模型幅度较小。
  • 决策曲线分析显示,与当前实践中使用的传统模型相比,所有机器学习模型均带来增量净获益。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 所有模型随时间出现校准漂移,机器学习模型幅度较小。
  • 仍有改进空间,可能来自新型生物学和/或影像生物标志物的整合。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Predictive tools can be useful for adapting surveillance or including patients in adjuvant trials after surgical resection of nonmetastatic renal cell carcinoma (RCC). Current models have been built using traditional statistical modelling and prespecified variables, which limits their performance. OBJECTIVE: To investigate the performance of machine learning (ML) framework to predict recurrence after RCC surgery and compare them with current validated models. DESIGN, SETTING, AND PARTICIPANTS: In this observational study, we derived and tested several ML-based models (Random Survival Forests [RSF], Survival Support Vector Machines [S-SVM], and Extreme Gradient Boosting [XG boost]) to predict recurrence of patients who underwent radical or partial nephrectomy for a nonmetastatic RCC, between 2013 and 2020, at 21 French medical centres. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary end point was disease-free survival. Model discrimination was assessed using the concordance index (c-index), and calibration was assessed using the Brier score. ML models were compared with four conventional prognostic models, using decision curve analysis (DCA). RESULTS AND LIMITATIONS: A total of 4067 patients were included in this study (3253 in the development cohort and 814 in the validation cohort). Most tumours (69%) were clear cell RCC, 40% were of high grade (nuclear International Society of Urological Pathology grade 3 or 4), and 24% had necrosis. Of the patients, 4% had nodal involvement. After a median follow-up of 57 mo (interquartile range 29-76), 523 (13%) patients recurred. ML models obtained higher c-index values than conventional models. The RSF yielded the highest c-index values (0.794), followed by S-SVM (c-index 0.784) and XG boost (c-index 0.782). In addition, all models showed good calibration with low integrated Brier scores (all integrated brier scores <0.1). However, we found calibration drift over time for all models, albeit with a smaller magnitude for ML models. Finally, DCA showed an incremental net benefit from all ML models compared with conventional models currently used in practice. CONCLUSIONS: Applying ML approaches to predict recurrence following surgical resection of RCC resulted in better prediction than that of current validated models available in clinical practice. However, there is still room for improvement, which may come from the integration of novel biological and/or imaging biomarkers. PATIENT SUMMARY: We found that artificial intelligence algorithms could better predict the risk of recurrence after surgery for a localised kidney cancer. These algorithms may help better select patients who will benefit from medical treatment after surgery.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Khene ZE, Bigot P, Doumerc N, et al. Application of Machine Learning Models to Predict Recurrence After Surgical Resection of Nonmetastatic Renal Cell Carcinoma. Eur Urol Oncol. 2022. PMID: 35987730. doi:10.1016/j.euo.2022.07.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。